Health-Related quality-Of-Life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer

Annals of Oncology

Volumn 24, Issue 10, 2013, Pages 2630-2635

  Cortes J ^a   Baselga, J ^b   Im, Y H ^c   Im, S A ^d   Pivot, X ^e   Ross, G ^f   Clark, E ^f   Knott, A ^f   Swain, S M ^g  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

^e UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^f ROCHE PRODUCTS LTD   (United Kingdom)

^g WASHINGTON CANCER INSTITUTE   (United States)

Author keywords

Docetaxel; Health Related quality of life; Metastatic breast cancer; Pertuzumab; Trastuzumab

Indexed keywords

DOCETAXEL; PERTUZUMAB; PLACEBO; TRASTUZUMAB;

ARTICLE; BREAST CANCER SUBSCALE SCORE; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL ASSESSMENT OF CANCER THERAPY BREAST QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TRIAL OUTCOME INDEX PHYSICAL FUNCTIONAL BREAST SCORE;

DOCETAXEL; HEALTH-RELATED QUALITY-OF-LIFE; METASTATIC BREAST CANCER; PERTUZUMAB; TRASTUZUMAB;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; NEOPLASM METASTASIS; PLACEBOS; QUALITY OF LIFE; QUESTIONNAIRES; RECEPTOR, ERBB-2; SURVIVAL; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84884644183     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt274     Document Type: Article

References (29)

1. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
2. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23: 4265-4274.
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672.
4. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
5. Franklin MC, Carey KD, Vajdos FF et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5: 317-328.
6. Agus DB, Akita RW, Fox WD et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2: 127-137.
7. Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004; 64: 2343-2346.
8. Baselga J, Gelmon KA, Verma S et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010; 28: 1138-1144.
9. Cortes J, Fumoleau P, Bianchi GV et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012; 30: 1594-1600.
10. Gianni L, Pienkowski T, Im YH et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13(1): 25-32.
11. Baselga J, Bradbury I, Eidtmann H et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379(9816): 633-640.
12. Blackwell KL, Burstein HJ, Storniolo AM et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumabrefractory metastatic breast cancer. J Clin Oncol 2010; 28: 1124-1130.
13. Brady MJ, Cella DF, Mo F et al. Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument. J Clin Oncol 1997; 15: 974-986.
14. National Comprehensive Cancer Network. Data needs: assessing guidance, endpoints, and patient-reported outcomes in oncology clinical care. http://www.nccn.org/about/news/ebulletin/2012-04-30/data_needs.asp.
15. Bezjak A, Ng P, Skeel R et al. Oncologists' use of quality of life information: results of a survey of Eastern Cooperative Oncology Group physicians. Qual Life Res 2001; 10: 1-13.
16. Meldahl ML, Acaster S, Hayes RP. Exploration of oncologists' attitudes toward and perceived value of patient-reported outcomes. Qual Life Res 2012; 22: 725-731.
17. Goodwin PJ, Black JT, Bordeleau LJ et al. Health-related quality-of-life measurement in randomized clinical trials in breast cancer-taking stock. J Natl Cancer Inst 2003; 95: 263-281.
18. Lemieux J, Goodwin PJ, Bordeleau LJ et al. Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009). J Natl Cancer Inst 2011; 103: 178-231.
19. Osoba D, Slamon DJ, Burchmore M et al. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 2002; 20: 3106-3113.
20. Wu Y, Amonkar MM, Sherrill BH et al. Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Ann Oncol 2011; 22: 2582-2590.
21. Baselga J, Cortes J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-119.
22. Swain S, Kim S-B, Cortés J et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 2013; 14: 461-471.
23. Eton DT, Cella D, Yost KJ et al. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol 2004; 57: 898-910.
24. Walker MS, Hasan M, Yim YM et al. Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients. Health Qual Life Outcomes 2011; 9: 46.
25. Sledge GW, Neuberg D, Bernardo P et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003; 21: 588-592.
26. Baselga J, Cortés J, Im Y-H et al. Adverse events with pertuzumab and trastuzumab: evolution during treatment with and without docetaxel in CLEOPATRA. J Clin Oncol 2012; 30(15 Suppl): Abstract 597.
27. Rugo H, Brammer M, Zhang F et al. Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials. Clin Breast Cancer 2010; 10: 288-293.
28. Sherrill B, Di Leo A, Amonkar MM et al. Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. Curr Med Res Opin 2010; 26: 767-775.
29. Zhou X, Cella D, Cameron D et al. Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat 2009; 117: 577-589.